Enhancing Efficacy of Immunotherapy and Chemo-Therapy Treatments

Abstract

Researchers at the University of California, Davis campus have discovered the use of certain compounds as immunomodulators for enhancing the efficacy of immunotherapy and chemoradiotherapy.

Full Description

Human cancers frequently express tumor associated antigens (TAA) that are altered forms of self-proteins or epitopes with limited or no expression in normal cells.  The identification of TAAs in cancer has made the development of cancer immunotherapies an attractive area of pharmaceutical research.  The efficacy of chemotherapy is known to be affected by inflammation, which is also a target for novel therapeutic strategies.  Agents that regulate the inflammatory microenvironment created by tumorgenesis and chemotherapy may improve the response to both cancer immunotherapies and chemo-radiotherapy through immunomodulation. 

UC Davis researchers have discovered the use of previously known compounds for immunomodulation of chemo-radiotherapy and immunotherapy. 

Applications

Cancer therapy

Features/Benefits

Improved Efficacy for Immunotherapy and Chemotherapy

Patent Status